Consumer protection bill
This article was originally published in The Tan Sheet
Executive Summary
HR 2621 moves to Senate after passing House June 11 by voice vote. Measure would amend the Federal Anti-Tampering Act by making it a crime to "knowingly stamp, print, place or insert any writing in or on any consumer product...prior to its sale" without consent of the product's manufacturer, distributor or retailer. Consumer Product Protection Act of 2002, introduced last July by Rep. Melissa Hart (D-Penn.) and amended May 8, was spurred by recent product tampering cases primarily in the food industry...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.